TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22182309

Group type: COMPARATOR
Intervention: Usual care group (7 core contacts with a provider of government funded 'Well Child' care over 2 years)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Food, Activity and Breastfeeding group (8 extra parent contacts over the first 2 years of life)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Sleep group (at least 3 extra parent contacts over the first 6 months of life)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Combination group (all extra contacts)
Number of subjects: 800
Study: 19719910

Group type: EXPERIMENTAL
Intervention: Telbivudine 600 mg once daily
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no antiviral treatment)
Number of subjects: 61
Study: 21242071

Group type: EXPERIMENTAL
Intervention: Saffron odor
Number of subjects: 35
Study: 15937632

Group type: EXPERIMENTAL
Intervention: Nurse-led education programme (PEP) consisting of a home visit and four 1-hour teaching sessions.
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control practices (standard care).
Number of subjects: 170
Study: 12223140

Group type: EXPERIMENTAL
Intervention: Oxymatrine
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Oxymatrine with Ara‐AMP
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: IFN‐a1b
Number of subjects: 196

Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 196
Study: 9818712

Group type: EXPERIMENTAL
Intervention: 20 mg fexofenadine HCl
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 60 mg fexofenadine HCl
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 120 mg fexofenadine HCl
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 240 mg fexofenadine HCl
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Single-dose administration
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Multiple-dose administration
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Urinary elimination
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: R(+) and S(‐) fexofenadine
Number of subjects: 24
Study: 7646652

Group type: EXPERIMENTAL
Intervention: Systemic flurbiprofen; appropriate doses not specified
Number of subjects: 0
Study: 2575765

Group type: EXPERIMENTAL
Intervention: Cavain (2 x 200 mg daily)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 30768

Group type: EXPERIMENTAL
Intervention: Lorazepam 3.0 mg b.i.d. for 4 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 11557486

Group type: EXPERIMENTAL
Intervention: Ethambutol (15 mg/kg of body weight) administered orally once daily to subjects with AIDS and healthy volunteers.
Number of subjects: 40
Study: 31924955

Group type: EXPERIMENTAL
Intervention: Genetically determined height (1 standard deviation higher, equivalent to 6.5 cm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjustment for potential mediators (lipids, blood pressure, glycaemic traits, body mass index, socio‐economic status)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lung function (measured by FEV1 and FVC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Height
Number of subjects: 0
Study: 29974725

Group type: EXPERIMENTAL
Intervention: Phytotherapic combination of L-Methionine, Hibiscus sabdariffa, and Boswellia serrata (1 tablet in the morning and 1 tablet in the evening for 7 days)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Short term antibiotic treatment according to international guidelines recommendations
Number of subjects: 93
Study: 25620034

Group type: EXPERIMENTAL
Intervention: Breathing exercises with positive expiratory pressure (10-15 cmH2O), 30 slow deep breaths twice a day for 2 months
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no breathing exercises)
Number of subjects: 48
Study: 23953402

Group type: EXPERIMENTAL
Intervention: i-scan imaging
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: acetic acid
Number of subjects: 95

Group type: COMPARATOR
Intervention: random biopsies
Number of subjects: 95
Study: 22744417

Group type: EXPERIMENTAL
Intervention: Traditional strength training (TS)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of mATPase histochemistry and MHC immunohistochemistry
Number of subjects: 16

Group type: COMPARATOR
Intervention: Non-exercising control (C)
Number of subjects: 16
Study: 20228974

Group type: EXPERIMENTAL
Intervention: DynaMatrix membrane
Number of subjects: 6

Group type: COMPARATOR
Intervention: Autogenous gingival graft
Number of subjects: 6
Study: 17403707

Group type: EXPERIMENTAL
Intervention: Alfentanil 36-40 microg kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Alfentanil 0 microg kg‐1 (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Alfentanil doses of 15, 30, 45 microg kg‐1
Number of subjects: 60
Study: 14978366

Group type: EXPERIMENTAL
Intervention: Midazolam/Meperidine (MM)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Midazolam/Placebo (MP)
Number of subjects: 100
Study: 12195604

Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 0
Study: 9814496

Group type: EXPERIMENTAL
Intervention: Obese urban black women (BW)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Obese urban white women (WW)
Number of subjects: 20
Study: 7657272

Group type: EXPERIMENTAL
Intervention: 12-month treatment starting with 6 MU three times a week, decreasing dose based on serum ALT (Group A: 59 cases)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Fixed dose of 3 MU three times a week for 12 months (Group B: 61 cases)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Fixed dose of 6 MU three times a week for 6 months (Group C: 54 cases)
Number of subjects: 174
Study: 2503945

Group type: COMPARATOR
Intervention: Sublingual Nitroglycerin
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Sublingual Nifedipine
Number of subjects: 78
Study: 178838

Group type: EXPERIMENTAL
Intervention: Mithramycin at a dose of 25 mug/kg/day for 21 days
Number of subjects: 96

Group type: COMPARATOR
Intervention: Best conventional care (Control)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Mithramycin
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Radiotherapy (not specifically evaluated in the study)
Number of subjects: 96
Study: 30995312

Group type: EXPERIMENTAL
Intervention: 24-LIP diet
Number of subjects: 4176

Group type: EXPERIMENTAL
Intervention: 26-LIP diet
Number of subjects: 4176

Group type: EXPERIMENTAL
Intervention: 28-LIP diet
Number of subjects: 4176

Group type: EXPERIMENTAL
Intervention: 24% CP diet
Number of subjects: 4176

Group type: EXPERIMENTAL
Intervention: LIP diets
Number of subjects: 4176

Group type: EXPERIMENTAL
Intervention: Carcass yield for females
Number of subjects: 4176

Group type: EXPERIMENTAL
Intervention: HIP diets
Number of subjects: 4176

Group type: EXPERIMENTAL
Intervention: 26 and 28-LIP diets
Number of subjects: 4176
Study: 28333342

Group type: EXPERIMENTAL
Intervention: Faropenem (600 mg) + Amoxicillin/Clavulanic acid (500/125 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Rifampicin (10 mg/kg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Rifampicin (10 mg/kg) + Faropenem (600 mg) + Amoxicillin/Clavulanic acid (500/125 mg)
Number of subjects: 36
Study: 26066063

Group type: EXPERIMENTAL
Intervention: VEGF serum levels in stable COPD
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: ΔVEGF (increase in VEGF over time) in ProCOLD cohort
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: ΔVEGF in ProCOLD cohort
Number of subjects: 308
Study: 23862647

Group type: EXPERIMENTAL
Intervention: 120 mg/kg weekly intravenous alpha1-PI
Number of subjects: 30

Group type: COMPARATOR
Intervention: 60 mg/kg weekly intravenous alpha1-PI
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both doses
Number of subjects: 30
Study: 21209124

Group type: EXPERIMENTAL
Intervention: Stepwise radical endoscopic resection (SRER)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Focal endoscopic resection followed by radiofrequency ablation (ER/RFA)
Number of subjects: 47
Study: 18305082

Group type: EXPERIMENTAL
Intervention: Gelatin 4%
Number of subjects: 60

Group type: COMPARATOR
Intervention: HES 130/0.4 6%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Kidney function
Number of subjects: 60
Study: 17290656

Group type: EXPERIMENTAL
Intervention: Manual plus expert system intervention
Number of subjects: 1351

Group type: EXPERIMENTAL
Intervention: Manual alone
Number of subjects: 1351

Group type: EXPERIMENTAL
Intervention: TTM-based interventions
Number of subjects: 1351
Study: 12207105

Group type: EXPERIMENTAL
Intervention: Computer-guided behaviour therapy (BT)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Clinician-guided behaviour therapy (BT)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Behaviour therapy (BT)
Number of subjects: 153
Study: 10483277

Group type: EXPERIMENTAL
Intervention: Palliative accelerated irradiation (PAIR) with a total dose of 32 Gy (2 x 2 Gy/d)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional treatment with a total dose of 60 Gy (K60)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Both therapies (PAIR and conventional)
Number of subjects: 34
Study: 8552931

Group type: EXPERIMENTAL
Intervention: 2 mg sustained-release melatonin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 mg fast-release melatonin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 mg sustained-release melatonin (2-month treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1793876

Group type: EXPERIMENTAL
Intervention: 50 mg aspirin per day
Number of subjects: 427

Group type: COMPARATOR
Intervention: No aspirin or antiplatelet agents
Number of subjects: 427
Study: 7011010

Group type: EXPERIMENTAL
Intervention: Radiation therapy plus six cycles of adjuvant chemotherapy
Number of subjects: 318

Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Radiation therapy alone or radiation therapy plus chemotherapy
Number of subjects: 318
Study: 29209867

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied at 780 nm, masseter and temporal=5 J/cm2 (20 mW-0.5 W/cm2), TMJ area=7.5 J/cm2 (30 mW-0.8 W/cm2), eight sessions, twice a week.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo LLLT
Number of subjects: 64

Group type: COMPARATOR
Intervention: Without treatment (WT)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Active LLLT
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Women with low levels of anxiety, salivary cortisol below 10 ng/ml, and with contraceptive use
Number of subjects: 64
Study: 28258052

Group type: EXPERIMENTAL
Intervention: Dynamic GPS-based measures of walkability and recreation area exposure
Number of subjects: 249

Group type: COMPARATOR
Intervention: Static home-based measures of walkability and recreation area exposure
Number of subjects: 249
Study: 26471311

Group type: EXPERIMENTAL
Intervention: 100,000 IU oral D3 supplementation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 23616112

Group type: EXPERIMENTAL
Intervention: Seeing images of strongly liked red and green objects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Seeing images of strongly disliked red and green objects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evaluation of preferences for colored objects during exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exposure to colored objects with a 24-hour delay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imagining colored objects instead of seeing them
Number of subjects: 0
Study: 21515003

Group type: EXPERIMENTAL
Intervention: Camel Snus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General Snus (high nicotine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other tobacco products (Camel Snus, Marlboro Snus, Stonewall, Ariva)
Number of subjects: 0
Study: 19083662

Group type: EXPERIMENTAL
Intervention: Spray and stretch treatment (vapocoolant blend of pentafluoropropane and tetrafluoroethane)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Stretch only control group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Spray and stretch treatment
Number of subjects: 30
Study: 16451149

Group type: EXPERIMENTAL
Intervention: Intubating Laryngeal Mask (ILMA)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Laryngeal Tube (LT)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: CobraPLA (COB)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Oxygenation and ventilation parameters
Number of subjects: 96
Study: 12964946

Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation (nurse-facilitated, manual-based using the Heart Manual)
Number of subjects: 650

Group type: COMPARATOR
Intervention: Hospital-based cardiac rehabilitation (comprehensive cardiac rehabilitation in an out-patient setting)
Number of subjects: 650
Study: 10613781

Group type: EXPERIMENTAL
Intervention: Assist/control ventilation (A/C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Volume-targeted IMV
Number of subjects: 30

Group type: COMPARATOR
Intervention: Synchronized IMV (SIMV)
Number of subjects: 30
Study: 9083601

Group type: EXPERIMENTAL
Intervention: Parent-interactive (classroom curricula + parent-interactive component)
Number of subjects: 2392

Group type: EXPERIMENTAL
Intervention: Parent non-interactive (classroom curricula only)
Number of subjects: 2392

Group type: COMPARATOR
Intervention: Control (basic AIDS education ordinarily provided by the school)
Number of subjects: 2392
Study: 8181546

Group type: EXPERIMENTAL
Intervention: Viscous chemically‐cured sealant (Maximum Cure)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Non‐viscous visible light‐cured sealant (Transbond resin)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no sealant)
Number of subjects: 80
Study: 3372910

Group type: EXPERIMENTAL
Intervention: 2 units of intravenous glucagon
Number of subjects: 8

Group type: COMPARATOR
Intervention: 2 ml of saline (placebo)
Number of subjects: 8
Study: 28847438

Group type: EXPERIMENTAL
Intervention: 3.5h training intervention about patient education (video observation, simulated patient practice, structured feedback)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: 3.5h training intervention about patient education
Number of subjects: 164

Group type: COMPARATOR
Intervention: Wait-list control group (no training)
Number of subjects: 164
Study: 27855097

Group type: EXPERIMENTAL
Intervention: EPO treatment at the original dose plus intravenous iron dextran 200 mg every 3 weeks (Q3W) for 15 weeks
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: EPO treatment at the original dose plus intravenous iron dextran 100 mg, twice a week for 5 weeks
Number of subjects: 603

Group type: COMPARATOR
Intervention: Doubling the EPO dose without preplanned iron supplementation
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 603
Study: 25354103

Group type: EXPERIMENTAL
Intervention: Double-unit cord-blood transplantation
Number of subjects: 224

Group type: COMPARATOR
Intervention: Single-unit cord-blood transplantation
Number of subjects: 224
Study: 22836063

Group type: EXPERIMENTAL
Intervention: Continuous accelerated irradiation (CAIR: once per day, 7 days per week)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Concomitant accelerated boost (CB: once per day, 3 days per week, and twice per day, 2 days per week)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 345
Study: 20390354

Group type: EXPERIMENTAL
Intervention: Preoperative bowel preparation (BP)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Surgery without bowel preparation (BP)
Number of subjects: 86
Study: 17942331

Group type: EXPERIMENTAL
Intervention: Variolink II (groups 1, 3, 5, and 7)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: RelyX Unicem (groups 2, 4, 6, and 8)
Number of subjects: 80
Study: 16888454

Group type: EXPERIMENTAL
Intervention: Creatine (Cr) supplementation (20 g.d(‐1) for 7 d then 5 g.d(‐1) for 4‐7 d)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (Pla)
Number of subjects: 7
Study: 11991696

Group type: EXPERIMENTAL
Intervention: Pre-operative colour duplex marking
Number of subjects: 149

Group type: COMPARATOR
Intervention: Varicose vein surgery without pre-operative marking
Number of subjects: 149
Study: 9789579

Group type: EXPERIMENTAL
Intervention: Isometric training of the elbow flexor muscles
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Imagined isometric training
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control task involving lower limbs
Number of subjects: 54
Study: 7633103

Group type: EXPERIMENTAL
Intervention: Enhanced MT-GRE images
Number of subjects: 30

Group type: COMPARATOR
Intervention: Enhanced GRE images
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Visual assessment of enhanced MT-GRE images
Number of subjects: 30
Study: 2919775

Group type: EXPERIMENTAL
Intervention: Bupivacaine epidural analgesia (N = 20) for 26‐30 hours
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ketobemidone (control group, N = 20) for postoperative pain relief
Number of subjects: 40
Study: 333852

Group type: EXPERIMENTAL
Intervention: 0.07 mg/kg nalbuphine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.14 mg/kg nalbuphine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg pentazocine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg pentazocine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: nalbuphine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: pentazocine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: nalbuphine and pentazocine
Number of subjects: 100
Study: 6759060

Group type: EXPERIMENTAL
Intervention: Long-acting propranolol (160 mg once daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sustained-release clonidine (0.25 mg once daily)
Number of subjects: 20
Study: 29134819

Group type: EXPERIMENTAL
Intervention: Web-based intervention program
Number of subjects: 76

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 76
Study: 29343076

Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin 40 mg daily for 1 day before to 3 days after contrast administration
Number of subjects: 496

Group type: COMPARATOR
Intervention: Conventional dose atorvastatin 10 mg daily for 1 day before to 3 days after contrast administration
Number of subjects: 496
Study: 26938555

Group type: EXPERIMENTAL
Intervention: Nutrition education sessions (12-week program)
Number of subjects: 353
Study: 25066648

Group type: EXPERIMENTAL
Intervention: CDT including Bandage
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CDT including Bandage + Kinesio Tape(®)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CDT including Kinesio Tape(®) without bandage
Number of subjects: 45
Study: 22351696

Group type: EXPERIMENTAL
Intervention: CEF (cyclophosphamide-epirubicin-fluorouracil)
Number of subjects: 476

Group type: COMPARATOR
Intervention: CMF (cyclophosphamide-methotrexate-fluorouracil)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: CEF
Number of subjects: 476

Group type: COMPARATOR
Intervention: CMF
Number of subjects: 476
Study: 19028044

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg once in the morning for 7 days post-operation)
Number of subjects: 1126

Group type: COMPARATOR
Intervention: Standard pre- and postoperative therapy (control group B)
Number of subjects: 1126

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 1126
Study: 17574951

Group type: EXPERIMENTAL
Intervention: Neck muscle endurance (NME) treatment for patients with NP
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Neck muscle endurance (NME) treatment for patients with ACDF
Number of subjects: 203

Group type: COMPARATOR
Intervention: NME comparison between patients and controls
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: NME comparison between female patients with ACDF and NP
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Flexion/extension ratio in patients with NP
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Flexion/extension ratio in patients with ACDF
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Correlation between NME and Neck Disability Index
Number of subjects: 203
Study: 15237710

Group type: EXPERIMENTAL
Intervention: Obese children
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control children
Number of subjects: 39
Study: 11933130

Group type: EXPERIMENTAL
Intervention: Pycnogenol (360 mg per day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Venostasin (600 mg per day)
Number of subjects: 40
Study: 9862573

Group type: EXPERIMENTAL
Intervention: Linomide 5 mg or 10 mg p.o. daily for 2 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Alpha‐interferon added at 3 MU s.c. three times weekly, escalating by 3 MU per week up to 12 MU
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combination of Linomide and alpha‐interferon
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Linomide 5 mg for 2 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Overall response to treatment
Number of subjects: 31
Study: 8770850

Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator (t-PA) given in an accelerated dosing regimen
Number of subjects: 60000

Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 60000

Group type: COMPARATOR
Intervention: No reperfusion therapy
Number of subjects: 60000
Study: 2165889

Group type: EXPERIMENTAL
Intervention: Deep breaths during rest
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deep breaths during 50 W exercise
Number of subjects: 0
Study: 20551

Group type: EXPERIMENTAL
Intervention: 1 mg BS 100‐141
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2 mg BS 100‐141
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2 mg BS 100‐141 (crossover study)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 4 mg BS 100‐141 (crossover study)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.30 mg clonidine (crossover study)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31326730

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Control arm (standard therapy)
Number of subjects: 258
Study: 28593415

Group type: EXPERIMENTAL
Intervention: FROI with enhanced haptic feedback activated
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional grasper
Number of subjects: 20

Group type: COMPARATOR
Intervention: FROI with enhanced haptic feedback deactivated
Number of subjects: 20
Study: 26307603

Group type: EXPERIMENTAL
Intervention: LY2963016 (LY IGlar)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Lantus (IGlar)
Number of subjects: 211